Saturday 17 October 2026
Export AMLX’s income statement to Excel — free account
Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
26.34
1.31
−4.74%
Follow AMLX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(56.52%) | (61.59%) | (63.26%) | (74.73%) | |
| (48.67%) | (55.00%) | (58.49%) | (66.25%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(45.51%) | (48.04%) | (55.75%) | (64.61%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(1.66) | (1.31) | (1.13) | (1.18) | |
Free Cash Flow |
(154.52) | (123.48) | (124.53) | (130.72) | |
Capital Expenditures |
(0.07) | (0.14) | (4.13) | (4.14) | |
| Other line items | |||||
Cash ROIC |
(22.86%) | (19.84%) | (22.52%) | (26.68%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.03 | 0.85 | 0.80 | 0.83 | |
Depreciation/Fixed assets |
(14.24) | (16.13) | (18.70) | (18.88) | |
Capex/Depreciation |
0.01 | 0.03 | 1.04 | 1.10 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.65) | (1.30) | (1.09) | (1.14) | |
Capex per Share |
0.00 | 0.00 | (0.04) | (0.04) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates